FUNCTION: it is an Iron Supplement.

It elevates the serum iron concentration, which

then helps to form Hgb or trapped in the reticuloendothelial cells for storage and
eventual conversion to a usable form of iron.
DRUG NAME: FEOSOL
GENERIC NAME: ferrous sulfate
BRAND NAME/S: Feosol, Fer-Gen-Sol, Fer-in-Sol, Fer-In-Sol, Feratab,
FeroSul, Ferra T.D. Caps, Ferro-Bob, Lydia E. Pinkham, MyKidz Iron
10, Slow Fe, Slow Release Iron
DOSAGE/ROUTE/STANDARD DIRECTIONS:
Adults:
Daily requirements: Men, 10 mg/day PO; women, 18 mg/day PO: pregnant
and lactating women, 30-60mg/day PO
Replacement in iron-deficiency anemia: 90-300mg/day (6 mg/kg/day) PO for
approximately 6-10 mo maybe required.
Pediatric: 10-15mg/day PO daily requirements.
USE: Ferrous sulfate is used to treat iron deficiency anemia (a lack of red
blood cells caused by having too little iron in the body).
ABSORPTION: absorb rapidly in the intestine
EXCRETION: Unknown
SIDE EFFECT/ADVERSE REACTION: constipation, upset stomach, black or
dark-colored stools, temporary staining of the teeth. Signs of an allergic
reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or
throat.
NURSING CONSIDERATIONS: confirm the doctors order. Give the drug with meals
(avoiding coffee, egg, milk, tea). Warn patient that the stool maybe dark or green.
Arrange for periodic monitoring of Hct and Hgb levels. Assess for the reaction of the
drug for 5 hrs. Document the procedure.

FUNCTION: Oral anticoagulant, Coumarin derivative.

DRUG NAME: Warfarin
GENERIC NAME: Warfarin
BRAND NAME/S: Coumadin
DOSAGE/ROUTE/STANDARD DIRECTIONS:
Adults: 2-5mg/day PO. Adjust dosage according to PT response. For maintenance 2-
10 mg/day PO based on PT ratio or INR.
Geriatric patients: lower doses are usually needed; begin with saller doses than those
recommended for dults, and closely monitor PT or INR.

USE: Venous thrombosis and its extension, treatment, prophylaxis. Treatment of

thromboembolic complications of atrial fibrilliation with embolization and cardiac
valve replacement. Pulmonary embolism, treatment prophylaxis.
ABSORPTION: absorb in the intestines and crosses the placenta
EXCRETION: feces, urine
SIDE EFFECT/ADVERSE REACTION: alopecia, urticaria, dermatitis, nausea,
vomiting, anorexia, abdominal cramping, diarrhea, retroperitoneal hematoma,
priapism, nephropathy, red-orange urine.

NURSING CONSIDERATIONS: verify the doctor’s order. assess allergy to warfarin.

Do not use drug if the patient is pregnant (use contraceptives). Monitor closely PT
ratio and INR. Administer the drug in IV form if the client can not take it orally.
Document the procedure.

FUNCTION: it is a granulocyte colony-stimulating factor. Increases the production of

neutrophils within bone marrow with little effects on the production of other
hemopoietic drug.
DRUG NAME: Neupogen
GENERIC NAME: Filgrastim
BRAND NAME/S: Neopogen
DOSAGE/ROUTE/STANDARD DIRECTIONS:
Adults: 100-120mg PO TID or QID. Reduce dose when symptoms improve. Use up to
1,200 mg/day in severe urinary urgency following pelvic radiotherapy.

USE: To decrease the incidence of infection in patients with nonmyeloid mlignancie

receiving myelosuppressive anticancer drugs . to reduce the time of neutrophil
recovery and duration of fever, following induction or consoliadation chemotherapy
treatment for acute myeloid leukemia. Treatment of severe chronic neutropenia.
ABSORPTION: absorb in the intestine and crosses the placenta
EXCRETION: Unknown
SIDE EFFECT/ADVERSE REACTION: headache, fever generalized weakness,
fatigue, alopecia, rash, nausea, vomiting, stomatitis, anorexia, bone pain,
generalized pain.
NURSING CONSIDERATIONS: Verify the doctor’s order. hypersensitivity to E. coli
products, pregnancy, lactation. Obtain CBC and platelet count before and twice
weekly before therapy. Doses maybe increase after chemotherapycycles. Do not give
the drug within 24hr after the chemotherapy. Document the procedure.

FUNCTION: it is an anticoagulant. It inactivate factor XA, therefore inhibiting

thrombus and clot formation by blocking the conversion of prothrombin to
thromboplastin and fibrinogen to fibrin, the final steps in clotting process.
DRUG NAME: Heparin
GENERIC NAME: Heparin
BRAND NAME/S: Hepalean, Heparin Leo
DOSAGE/ROUTE/STANDARD DIRECTIONS:
Adults:
 Subcutaneous (deep subcutaneous injection) – IV loading dose 5,000 units the
10,000-20,000 units ubcutaneously followed by 8,000-10,000 units q 8hr or 15,000-
20,000 q 12hr.
Intravenous – initial dose of 10,000 units and then 5,000-10,000 units q 4-6hr
thereafter for 7 days or until patient is fully ambulatory.

USE: For the prevention and treatment of venous thrombosis and pulmonary
embolism. For the treatment of atrial fibrillation with embolization. Diagnosis and
treatment of DIC. Prevention of clotting in blood samples and heparin lock sets during
dialysis procedure.
ABSORPTION: broken down in the liver
EXCRETION: Urine
SIDE EFFECT/ADVERSE REACTION: loss of hair, bruising,
thrombocytopenia, elevated AST, ALT levels, hyperkalemia, chills, fever,
urticaria, asthma
NURSING CONSIDERATIONS: Verify the doctor’s order. Assess for recent surgery
or injury; sensitivity to heparin; hyperlipidemia; pregnancy. Adjust dose according to
coagulation test results performed just before injection (30 min before each
intermittent dose or q 4-6 hr if continous IV dose). Therapeutic range aPTT: 1.5-2.5
times control. Always check compatibilities with other IV solutions. Use heparin
locked needles to avoid repeated injections. Give deep subcutaneous injection; do not
give heparin by IM injection. Document the procedure.

FUNCTION: it is a thrombolytic agent.

DRUG NAME: Urokinase
GENERIC NAME: Urokinase
BRAND NAME/S: Abbokinase
DOSAGE/ROUTE/STANDARD DIRECTIONS:
Adults – give through constant infusion pump: Priming dose of 4,400 IU/kg as an
admixture with 5% dextrose injection or 0.9% sodium chloride at rate of 90 ml/hr over
10 min. Then give 4, 400 UI/kg/hr at a rate of 15ml/hr for 12 hr. At the end of
infusion, flush the tubing wit 0.9% of sodium chloride or 5% dextrose injection equal
to the volume of the tubing. At the end of infusion, treat with continous heparin IV
infusion.

USE: For lysis of pulmonary emboli or pulmonary emboli with unstable

hemodynamics in adults.
ABSORPTION: absorb in the intestine and crosses the placenta and in the breast milk
EXCRETION: Unknown
SIDE EFFECT/ADVERSE REACTION: headache, angionorotic edema,
arrhythmias, skin rash, uticaria, itching, flushing, bleding. Difficulty of
breathing, bronchospasm.
NURSING CONSIDERATIONS: Verify the doctor’s order. assess history of
hypersensitivity to urokinase. Regulary monitor coagulation studies. Apply pressure or
pressure dressing to control superficial bleeding. Avoid any arterial invasive
procedures. Arrange for blood typing and cross matching of blood if serious blood loss
occurs. Document the procedure.

FUNCTION: it is a synthetic vitamin, it allows the absorption of vitamin B12, which

is essential to cell growth and reproduction, hematopoeisis and nucleoprotein.
DRUG NAME: Vitamin B12 (intranasal)
GENERIC NAME: Cyanocobalamin
BRAND NAME/S: Vitamin B12
DOSAGE/ROUTE/STANDARD DIRECTIONS: One spray (500mcg) in one nostril,
once per week.

USE:Maintenance of patient in hematologic remission after IM vit B12 therapy for

pernicious anemia. Maintenance in therapeutic levels of vitamin B12 in patients with
HIV, AIDS, MS, and Chrons disease.
ABSORPTION: absorb in the intestine and amy cross in the placenta and breast milk.
EXCRETION: Unknown
SIDE EFFECT/ADVERSE REACTION: headache, bone marrow suppression,
rhinitis, nasal congestion, fever, pain, local irritation.

NURSING CONSIDERATIONS: Verify the doctor’s order . confirm diagnosis before

administering the drug. Monitor serum of vitamin B12. Document the procedure.

FUNCTION: it is a Immunostimulant . Treatment of Anemia of Chronic Renal

Failure
DRUG NAME: Epogen Factor VIII
GENERIC NAME: Epoetin Alfa
BRAND NAME/S: Epogen
DOSAGE/ROUTE/STANDARD DIRECTIONS:
Starting Dose:
Adults
Pediatric Patients
50 to 100 Units/kg TIW; IV or SC
50 Units/kg TIW; IV or SC Increase Dose by 25% If: 1. Hemoglobin is
< 10 g/dL and has not increased by 1 g/dL after 4 weeks of therapy
or
2. Hemoglobin decreases below 10 g/dL Reduce Dose by 25%
When: 1. Hemoglobin approaches 12 g/dL or,
2. Hemoglobin increases > 1 g/dL in any 2-week period

USE: is indicated for the treatment of anemia in patients with chronic

renal failure (CRF) on dialysis. EPOGEN® is indicated to elevate or
maintain the red blood cell (RBC) level and to decrease the need for
transfusions in these patients.
ABSORPTION: unknown
EXCRETION: t 1/2
• SIDE EFFECT/ADVERSE REACTION: chest pain or heavy feeling, pain
spreading to the arm or shoulder, nausea, sweating, general ill feeling;
• feeling short of breath, even with mild exertion;
• sudden numbness or weakness, especially on one side of the body;
• sudden headache, confusion, problems with vision, speech, or balance;
or
• pain or swelling in one or both legs.

eeling short of breath, even with mild exertion;

swelling of your ankles or feet;
increased blood pressure (severe headache, blurred vision, trouble
concentrating, chest pain, numbness);
feeling light-headed, fainting; or
seizure (black-out or convulsions).
NURSING CONSIDERATIONS: check the doctor’s order. Assess for history of
allergy to epogen. Observe for the action of the drug or its reaction in 5hrs. Document
the procedure.